ClinicalTrials.gg
Not yet recruitingNCT07557290MG-MTA-RCT2026Updated Apr 29, 2026

Comparative Evaluation of Clinical and Radiographic Outcomes of Mustard Gel (Brassica Nigra) and Mineral Trioxide Aggregate (MTA) as Pulpotomy Agents in Deciduous Molars- A Randomized Controlled Trial

A Phase 1 interventional study of Intervention 1: Mustard Gel and Intervention 2 : Mineral Trioxide Aggregate (MTA) in Dental Pulp Exposure, sponsored by Dr Nida Farooq. Not yet recruiting. Open to participants aged 6 Years to 8 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Dr Nida Farooq · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
6 Years to 8 Years
Sex
All
01

Study summary

The aim of this clinical trial is to compare two materials to treat baby molars with deep cavities. When the cavity is very deep and reaches the nerve of a baby tooth, dentist perform a treatment called "Pulpotomy". This means removing the damaged part of the nerve and placing medicament on healthy part to help tooth heal and stay pain-free until it falls out naturally. The standard medicine used today is Mineral Trioxide Aggregate (MTA) for treating baby molars that have deep cavities. It works well but is expensive and can darken the tooth. The study is testing a new medicine called Mustard Gel , made from black mustard seeds and may help heal the tooth. Mustard has natural healing and germ-fighting properties.This trial will help to compare Mustard Gel with MTA to see if the agent works to treat pulpitis.

Children aged 6-8 years who need a pulpotomy procedure on a baby molar will be selected. During this procedure, infected part of the pulp tissue will be removed and medicament will be placed over the remaining healthy pulp.

Selected participants will be put into one of the two groups by chance:

  1. Mustard Gel Group : tooth will be treated with mustard gel after nerve removal
  2. MTA Group : tooth will be treated with MTA, the current standard material. All the teeth will be sealed with a permanent filling material.Participants will be treated with both drugs and monitored after about 1 week, 1 month and 3 months to see if the tooth is pain-free and looks healthy on X-ray. The study will help check if Mustard gel is safe and if it causes any side effects.
02

Conditions studied

  • Dental Pulp Exposure

Browse trials for

Keywords

  • Herbal Pulptomy agents for primary molars
03

In context

Dental Pulp Exposure

31 studies on the registry are indexed under Dental Pulp Exposure; 5 are open to participants now.

This study's planned enrollment of 72 is above the median of 53 across 29 interventional studies indexed under Dental Pulp Exposure.

Browse Dental Pulp Exposure studies →

Lead sponsor

This is the only study on the registry with Dr Nida Farooq as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy co-operative children 6-8 years old
  • primary molars with deep cavities and iatrogenic pulp exposure
  • clinically with no sign of spontaneous pain, sinus tract, tenderness to percussion, pathological mobility
  • radiographically with absence of periapical radiolucency, internal/external root resorption, furcal radiolucency
  • hemorrhage at the site of amputation controlled with 5 minutes
  • tooth should be vital with healthy peridontium
  • tooth should be restoreable

Exclusion criteria

Exclusion Criteria:

  • teeth without permanent successor
  • teeth with history of irreversible pulpitis
  • post amputation unsuccessful hemorrhage control even after 5 minutes
  • radiographic evidence of internal/external root resorption, furcal/periapical pathology
  • patients with drug allergies or systemic diseases
  • clinical signs of spontaneous pain, sinus tract, tenderness to percussion, pathological mobility
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Arm A : Mustard Gel Pulpotomy

    Primary molars will undergo pulpotomy followed by application of Mustard Gel in as pulpotomy medicament. After the removal of coronal pulp tissue and hemostasis the mustard gel will be applied directly over the radicular pulp stumps under aseptic conditions followed by the placement of suitable base and permanent filling material to seal tooth. Clinical and radiographic follow up will be done at 1 week, 1 month, and 3 months.

    Drug: Intervention 1: Mustard Gel

  • Active comparator
    Arm B: Mineral Trioxide Aggregate Pulpotomy

    MTA will be used as pulpotomy agent in decidoud molars following standard clinical procedure after coronal pulp amputation. The treated tooth will be restored with appropriate base and final restoration. Clinical and radiographic follow up will be done at 1 week, 1 month and 3 months.

    Drug: Intervention 2 : Mineral Trioxide Aggregate (MTA)

Interventions

  • DrugIntervention 1: Mustard Gel

    Drug pages: MechlorethamineStudies of MechlorethamineMechlorethamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Mustard GasStudies of Mustard GasMustard Gas pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Gel obtained from Brassica nigra (Black Mustard) seeds will be used as pulpotomy medicament in primary molars placed over pulp stumps after coronal pulp amputation. Approximately 1mm of mustard gel will be applied and tooth will be sealed with permanent filling material.

  • DrugMineral trioxide aggregateStudies of Mineral trioxide aggregateMineral trioxide aggregate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MTA will be mixed according to manufacturer's instructions and placed over the pulp stumps to a thickness of 1-2 mm using an amalgam carrier. It will be compressed gently with damp cotton pellet, the restored with glass-ionomer cement.

06

What researchers measure

Primary outcomes

  1. Clinical and Radiographic success rate of Pulpotomy

    The proportion of the teeth treated with pulpotomy that show clinical and radiographic success. Clinical success rate is defined as absence of pain, swelling, abscess or pathological mobility. Radiographic success is defined as absence of internal/external root resorption, furcal/periapical radiolucency or widened PDL space. assessment will be done using clinical examination and periapical radiographs.

    Time frame: At 1 week, 1 month, 3 months post treatment.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Jun 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartEst.
Apr 20, 2026
Primary completionEst.
Jun 2026
CompletionEst.
Aug 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07557290
Lead sponsor
Dr Nida Farooq
Responsible party
Dr Nida Farooq (Post Graduate Resident, Department of Operative Dentistry, Postgraduate Medical Institute, Lahore) — Sponsor-investigator
First posted
Apr 29, 2026
Start date
Apr 20, 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Apr 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mechlorethamine · Mustard Gas

Start the discussion